• LAST PRICE
    5.9050
  • TODAY'S CHANGE (%)
    Trending Down-0.0850 (-1.4190%)
  • Bid / Lots
    5.9000/ 4
  • Ask / Lots
    5.9100/ 5
  • Open / Previous Close
    5.9700 / 5.9900
  • Day Range
    Low 5.8000
    High 6.0000
  • 52 Week Range
    Low 5.2500
    High 22.7500
  • Volume
    92,804
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 5.99
TimeVolumeTVTX
09:32 ET165716
09:34 ET8965.95
09:36 ET2005.83
09:38 ET88545.88
09:39 ET2005.87
09:41 ET4005.84
09:43 ET4005.85
09:45 ET39085.83
09:48 ET12095.845
09:50 ET9645.82
09:52 ET8005.8
09:54 ET150005.92
09:56 ET17125.89
09:57 ET40655.88
09:59 ET12005.86
10:01 ET34575.8652
10:03 ET15005.875
10:06 ET35285.82
10:08 ET25465.865
10:10 ET17005.89
10:12 ET2005.88
10:14 ET36505.9
10:15 ET19325.91
10:17 ET15755.905
10:19 ET15995.905
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTVTX
Travere Therapeutics Inc
455.9M
-1.2x
---
United StatesCDMO
Avid Bioservices Inc
424.3M
-37.3x
---
United StatesTRDA
Entrada Therapeutics Inc
410.6M
-47.8x
---
United StatesHRTX
Heron Therapeutics Inc
416.4M
-3.3x
---
United StatesKMDA
Kamada Ltd
292.0M
29.0x
-22.48%
United StatesANIK
Anika Therapeutics Inc
376.1M
-4.5x
---
As of 2024-04-18

Company Information

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Contact Information

Headquarters
3611 Valley Centre Dr, Suite 300SAN DIEGO, CA, United States 92130
Phone
760-260-8600
Fax
302-645-1280

Executives

Independent Chairman of the Board
Gary Lyons
President, Chief Executive Officer, Director
Eric Dube
Chief Financial Officer
Christopher Cline
Senior Vice President, General Counsel, Corporate Secretary
Elizabeth Reed
Senior Vice President - Research and Development
William Rote

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$455.9M
Revenue (TTM)
$145.2M
Shares Outstanding
76.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.68
EPS
$-4.98
Book Value
$2.66
P/E Ratio
-1.2x
Price/Sales (TTM)
3.1
Price/Cash Flow (TTM)
---
Operating Margin
-267.24%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.